Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522129 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 1 study, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03522129 is a Phase 1 study that has completed, run by Cognition Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT03522129, a Phase 1 study, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
Interventions
- DRUG Placebo
- DRUG CT1812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2019-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03522129
The ClinicalTrials.gov registry entry for NCT03522129 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cognition Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03522129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03522129 about?
NCT03522129 is a clinical study titled "Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease". This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
What is the current status of trial NCT03522129?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-05-30. Estimated completion is 2019-02-06.
What interventions are being tested in trial NCT03522129?
The interventions under investigation include: Placebo (DRUG), CT1812 (DRUG).
Who is sponsoring clinical trial NCT03522129?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.